- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06382480
PROTeIn-rijke maaltijden om de glucose onder controle te houden (PROTIME)
Op maaltijdtiming gebaseerde strategieën om het glucosemetabolisme bij prediabetes en diabetes type 2 te verbeteren
The overall aim is to identify the dietary pattern for prevention and treatment of type 2 diabetes. The specific aim of this pilot project is to compare effects of two diets with different diurnal distribution of carbohydrates and protein on the glucose metabolism in subjects with prediabetes and type 2 diabetes and its effects on inflammatory status.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Overweight individual with prediabetes and non-insulin treated type 2 diabetes will be recruited for the study. The trial will have a cross-over design and compare metabolic effects of two isocaloric 4-week interventions with opposite timely distribution of macronutrient intake - a high-protein (HP) breakfast and a high-carb (HC) dinner (HP/HC intervention) vs. a HC breakfast and a HP dinner (HC/HP intervention) - divided by a 4-week wash-out phase. A HP low-carb meal (breakfast or dinner) will contain 35%E protein, 35%E carbs, and 30%E fat, and a HC meal (breakfast or dinner) will contain 10E%protein, 60%E carbs, and 30%E fat.
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
Potsdam-Rehbrücke
-
Potsdam, Potsdam-Rehbrücke, Duitsland, 14558
- Olga Ramich
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Prediabetes (fasting blood sugar 100-125 mg/dl)
- Diabetes type 2 (fasting blood sugar >126 mg/dl)
- Overweight and obesity (BMI 25-50 kg/m2)
Exclusion Criteria:
- Other diabetes types
- Insulin treatment
- Shift work
- Weight changes >5% within past 3 months
- Systemic glucocorticoid therapy
- Systemic infections
- Severe anemia
- High blood pressure (>180/110 mmHg)
- Endocrinologic, liver and heart disorders
- Immune diseases
- Thyroid dysfunction
- Heart attack or stroke
- Cancer in the last 2 years
- Eating disorders, food intolerance/allergy, addiction disorders, digestive disorders intestinal, liver, cardiovascular diseases
- Hereditary or acquired coagulation disorders
- Non-interruptible intake of blood thinners (anticoagulants)
- Specific diets, intermittent fasting
- Pregnancy or breastfeeding
- Severe internal or psychiatric disorders or other conditions and drugs therapy that might influence the outcome of the study
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Ondersteunende zorg
- Toewijzing: Gerandomiseerd
- Interventioneel model: Crossover-opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: HP/HC - HC/HP
Isocaloric 4-week HP/HC intervention followed by a 4-week HC/HP intervention. |
The intervention is about an isocaloric diet that differs in terms of distribution of carbohydrates and protein throughout the day. The interventions include a HP-breakfast and a HC-dinner vs. a HC-breakfast and a HP-dinner. A HP low-carb meal (breakfast or dinner) will contain 35%E protein, 35%E carbs, and 30%E fat, and a HC meal (breakfast or dinner) will contain 10%E protein, 60%E carbs, and 30%E fat. |
|
Experimenteel: HC/HP - HP/HC
Isocaloric 4-week HC/HP intervention followed by a 4-week HP/HC intervention. |
The intervention is about an isocaloric diet that differs in terms of distribution of carbohydrates and protein throughout the day. The interventions include a HP-breakfast and a HC-dinner vs. a HC-breakfast and a HP-dinner. A HP low-carb meal (breakfast or dinner) will contain 35%E protein, 35%E carbs, and 30%E fat, and a HC meal (breakfast or dinner) will contain 10%E protein, 60%E carbs, and 30%E fat. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Mean 24-hour glucose
Tijdsspanne: 4 weeks
|
Mean 24-hour glucose assessed by continuous glucose monitoring (CGM) |
4 weeks
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Measurement of height
Tijdsspanne: 4 weeks
|
Height measured by stadiometer |
4 weeks
|
|
Measurement of body weight
Tijdsspanne: 4 weeks
|
Body weight measured by body scale |
4 weeks
|
|
Waist and hip circumference / waist to hip ratio
Tijdsspanne: 4 weeks
|
Waist and hip circumference measured by tape measure |
4 weeks
|
|
Systolic and diastolic blood pressure
Tijdsspanne: 4 weeks
|
Systolic and diastolic blood pressure changes measurement by manometer |
4 weeks
|
|
Body fat and lean mass
Tijdsspanne: 4 weeks
|
Body fat and lean mass assessed by bioelectrical impendance analysis (BIA) |
4 weeks
|
|
Energy expenditure and substrate oxidation rates
Tijdsspanne: 4 weeks
|
Energy expenditure and substrate oxidation rates assessed by indirect calorimetry |
4 weeks
|
|
Hepatic values (gamma-glutamyl transferase (GGT), aspartate aminotransferase (AST), alanine aminotransferase (ALT))
Tijdsspanne: 4 weeks
|
GGT, AST, ALT etermined in fasting blood samples |
4 weeks
|
|
Renal values (creatinine, urea, uric acid)
Tijdsspanne: 4 weeks
|
Renal values determined in fasting blood samples |
4 weeks
|
|
Intra- und inter-day glycemic variability
Tijdsspanne: 4 weeks
|
Indices of intra- and inter-day glycemic variability assessed by continuous glucose monitoring (CGM) |
4 weeks
|
|
Glucose levels in meal tolerance test (MTT)
Tijdsspanne: 4 weeks
|
Glucose levels in blood samples collected in MTT |
4 weeks
|
|
Metabolic hormones (insulin, C-peptide, glucagon, glucagon-like peptite 1(GLP-1), gastric inhibitory polypeptide (GIP), peptide YY (PYY), ghrelin, adiponectin, leptin)
Tijdsspanne: 4 weeks
|
Blood levels of metabolic hormones assessed in fasting state and during the MTT |
4 weeks
|
|
Inflammatory markers and T cell populations analyses
Tijdsspanne: 4 weeks
|
Level of the inflammatory markers IL-6, TNFa, MCP-1 and T cell populations in circulation and adipose tissue are assessed through blood analysis and fat biopsy |
4 weeks
|
|
Satiety and hunger scores
Tijdsspanne: 4 weeks
|
Satiety and hunger scores assessed using Visual Analog Scale (VAS with a scale of 1-100, where higher values correspond to stronger satiety/hunger) |
4 weeks
|
|
Sleep/wake timing and sleep quality
Tijdsspanne: 4 weeks
|
Sleep/wake timing and sleep quality assessed by the Pittsburgh Sleep Quality Index (PSQI score, which ranges from 0-21, where higher values correspond to worse sleep quality) and also monitored by an ActiGraph device |
4 weeks
|
|
Physical activity
Tijdsspanne: 4 weeks
|
24-h physical activity will be monitored by an ActiGraph device |
4 weeks
|
|
Adipose tissue transcriptome
Tijdsspanne: 4 weeks
|
RNA-Seq analysis of subcutaneous adipose tissue sample |
4 weeks
|
|
Gene expression in peripheral blood mononuclear cells (PBMC)
Tijdsspanne: 4 weeks
|
Expression of metabolic genes assessed by qPCR |
4 weeks
|
|
Gut microbiota and microbiome-derived metabolites
Tijdsspanne: 4 weeks
|
Determined in stool samples and blood plasma |
4 weeks
|
|
Determination of decision behavior
Tijdsspanne: 4 weeks
|
Impulsiveness assessed by decision making tasks on computer |
4 weeks
|
Medewerkers en onderzoekers
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Olga Ramich, PD Dr., German Institute of Human Nutrition
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Endocriene systeemziekten
- Voedingsstoornissen
- Metabole ziekten
- Overvoeding
- Lichaamsgewicht
- Glucosemetabolismestoornissen
- Suikerziekte
- Pathologische aandoeningen, tekenen en symptomen
- Voedings- en stofwisselingsziekten
- Tekenen en symptomen
- Overgewicht
- Obesitas
- Diabetes mellitus, type 2
- Prediabetische toestand
- Dieet, voedsel en voeding
- Fysiologische fenomenen
- Nutritionele fysiologische fenomenen
- Dieet
Andere studie-ID-nummers
- 90/2023
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .